Surgical management of stage-2 medication-related osteonecrosis of the jaw with transplantation of human amniotic membrane: Preliminary results
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Masson s.r.l.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Medication-related osteonecrosis of the jaw (MRONJ) is a drug adverse reaction. Seven osteonecrosis areas in 5 cases were treated with stage-2 MRONJ using human amniotic membrane (HAM) transplantation after sequestrectomy. Patients were evaluated in terms of infection (pain, erythema, and pus), mucosal coverage, and pain at 1, 2, 4, 8, and 12 weeks. Patients who showed improvement (total mucosal coverage, no sign of infection and pain) at the end of 12 weeks were followed up every 8 weeks. Also, radiographic examinations (panoramic radiography at every 8 weeks, cone-beam computed tomography at every 6 months) were performed to evaluate bone destruction. Complete mucosal closure was achieved in 6 necrosis sites. In only 1 patient, mucosal coverage was not achieved. No pain and infection relapse were observed during the follow-ups. HAM might be an effective material in terms of soft tissue healing and elimination of pain and infection for stage-2 MRONJ. Clinical Trials Registration Number: NCT04967963 © 2021
Açıklama
Anahtar Kelimeler
Amniotic membrane, Bisphosphonates, Medication-related osteonecrosis of the jaw, MRONJ, Mucosal coverage, bone density conservation agent, amnion, case report, human, jaw osteonecrosis, pain, panoramic radiography, Amnion, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Humans, Pain, Radiography, Panoramic
Kaynak
Journal of Stomatology, Oral and Maxillofacial Surgery
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
123
Sayı
3
